Author: healthadmin
Members of a congressional subcommittee this week questioned public works leaders and state officials about their knowledge of existing problems with a sewer line that collapsed near the Potomac River on Jan. 19. The incident was “one of the largest sewage spills in U.S. history,” according to the University of Maryland School of Public Health. A portion of the 72-inch diameter Potomac Interceptor sewer pipe collapsed, spilling more than 242 million gallons of untreated wastewater into the Potomac River. In response to a question from Rep. John Joyce (R-Pennsylvania), the head of the utility company that oversees the Potomac Interceptor,…
The popular show “The Joe Rogan Experience” has gradually transformed from a comedy podcast to a highly influential platform with real-world political weight. Two new studies reveal that show viewership strongly predicts voting for Donald Trump in the 2024 presidential election, even after accounting for past voting habits. These results were recently published as a preprint. APSA Preprint. The media landscape has been fractured over the past two decades in the shadow of the modern Internet. Viewers now have a huge variety of channels to choose from, and entertainment programming has emerged as a prominent vehicle for political messages. Programs…
Adam Feuerstein is a senior writer and biotechnology columnist, reporting on the intersection of drug development, business, Wall Street, and biotechnology. He is co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. Signal’s Adam can be reached at stataf.54.A type of targeted chemotherapy developed by China-based Cologne Biotech and licensed to Merck & Co. reduced the risk of tumor progression in lung cancer patients by 65%, according to results from a phase 3 trial reported Thursday. The study also found a preliminary survival benefit in favor of Cologne Merck’s drug called sacituzumab…
Phase 3 data for Merck & Co. and Cologne Biotech’s antibody-drug conjugate sacituzumab tilmothecan (sac-TMT) suggest an intensifying race to establish a new standard of care in first-line non-small cell lung cancer. In previously untreated PD-L1-positive NSCLC, the combination of TROP2-directed ADC and Keytruda significantly reduced the risk of disease progression or death by 65% compared with Keytruda alone, according to an abstract presented in advance of the ASCO 2026 Annual Meeting. The p-value was less than 0.0001, suggesting high statistical significance. Although the important overall survival results underlying regulatory considerations in first-line NSCLC were not yet mature at the…
A federal appeals court on Thursday reversed a landmark ruling that ordered the EPA to address health risks from fluoride in drinking water, handing the agency a victory in a seven-year legal battle that has influenced federal policy and White House politics. The Ninth Circuit Court of Appeals found that the district court judge abused his discretion by “directing” the case, delaying sentencing, and requiring new evidence and a second court trial. The disposition in an unsigned memorandum issued Thursday sent the case back to the U.S. District Court for the Northern District of California, this time for resentencing based…
Scientists have developed a new artificial intelligence tool that can predict whether an adult has attention deficit hyperactivity disorder by examining their past medical records. This predictive model suggests that subtle patterns in daily medical visits can identify undiagnosed individuals months before doctors formally detect symptoms. This study was recently published in the journal european psychiatry. Attention-deficit hyperactivity disorder is a common neurodevelopmental disorder that affects approximately 5 to 7.2 percent of children and approximately 2.5 percent of adults worldwide. People with this condition experience varying degrees of inattention, hyperactivity, and impulsivity that interfere with daily life. It tends to…
A network of mail-order pharmacies, wholesalers and patient service organizations affiliated with the largest self-proclaimed Pentecostal sect in the United States has been accused of defrauding pharmaceutical giant Eli Lilly of more than $200 million through a multiyear kickback scheme centered on the diabetes drug Trulicity. In a federal lawsuit filed this week in Miami, Lilly’s lawyers accuse the Florida-based mail-order pharmacy Drug Place and several other companies (as well as individually named defendants) of operating “under the guise of a large-scale ‘prescription cost-sharing program’ for members of the Church of God in Christ.” “Lilly brought this lawsuit to stop…
Healthcare organizations remain at the forefront of pharmaceutical marketing, but new technologies and changing political dynamics are putting even more pressure on the industry. In this new series, Fierce Pharma Marketing digs into the key issues impacting agencies and pharmaceutical marketing with key executives from across the industry.In the first installment of the series, Fierce spoke with Shannon Walsh, Chief Operating Officer and President of PR, Social and Influence at Ogilvy Health. When it comes to AI, “things are moving at the speed of light,” Walsh said. “Every year, even within the last three months, we see significant changes in…
Researchers at Baylor College of Medicine and Okayama University in Japan have developed a promising new eye drop formulation to treat dry eye disease and tested it in mice. The team reports: Research Ophthalmology and Vision Science They found that the treatment significantly reduced typical dry eye features, including inflammation, damage to the ocular surface, and loss of goblet cells, which produce factors that help stabilize tears and lubricate the eye. This finding supports the conduct of human studies to evaluate the safety and effectiveness of this treatment, which could benefit millions of people with dry eye disease. Dry…
A new research paper has been published in Volume 13. oncology science April 2, 2026, titled “Selective Blood-Brain Barrier Penetration and Tumor Targeting of Nitrosylcobalamin in Glioblastoma: Pharmacokinetics, Tissue Distribution, and Synergy with TRAIL and Temozolomide.” The study was led by first and corresponding author Joseph A. Bauer of Nitric Oxide Services, LLC and Cleveland Clinic Foundation Taussig Cancer Center. In this study, the authors investigated whether nitrosylcobalamin (NO-Cbl), a vitamin B12 analog that releases nitric oxide, can selectively cross the blood-brain barrier (BBB) and target glioblastoma tissue. Glioblastoma multiforme (GBM) remains one of the deadliest and most treatment-resistant brain…